Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Both indoor and outdoor air quality impact chronic obstructive pulmonary disease (COPD), which opens up a large avenue to work with patients to improve their outcomes.For COPD patients, the adage ...

Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 ...

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

MONDAY, Oct. 7, 2024 (HealthDay News) -- Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according ...

The New England Journal of Medicine: "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts." FDA label: "DUPIXENT® (dupilumab) injection, for subcutaneous use." ...